Pharmacoeconomics of hepatitis C

P and T

Volumn 25, Issue 9, 2000, Pages 468-475

  Koff, R S ^a   Fendrick, M ^a  

^a UMASS/Memorial Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONSENSUS INTERFERON; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; REVIEW; TREATMENT OUTCOME;

EID: 0033828361     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Management of hepatitis C
2. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
3. Projecting the future healthcare burden from hepatitis C in the United States
4. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
5. Current practice patterns of primary care physicians in the management of patients with hepatitis C
6. The treatment of chronic viral hepatitis
7. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics following administration of ascending subcutaneous doses of pegylated interferon and interferon alfa-2a to healthy subjects
8. A controlled, randomized, multicenter, ascending-dose phase II trial of pegylated interferon alfa-2a vs standard interferon alfa-2a for treatment of chronic hepatitis C
9. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
10. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
11. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks vs interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
12. Estimates of the cost-effectiveness of a single course of interferon alfa-2b in patients with histologically mild chronic hepatitis C
13. The impact of surgical complications after liver transplantation on resource utilization
14. Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: A decision analysis
15. Cost-effectiveness of 6 and 12 months of interferon alfa therapy for chronic hepatitis C
16. Cost-effectiveness of initial ribavirin/interferon alfa-2b for chronic hepatitis C
17. Cost-effectiveness of assessment and management of risk factors
18. Chronic hepatitis C infection causes a significant reduction in quality of life in the absence of cirrhosis
19. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C
20. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy
21. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile
22. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response